Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 8
2004 8
2005 10
2006 16
2007 12
2008 15
2009 23
2010 41
2011 30
2012 38
2013 29
2014 31
2015 32
2016 37
2017 40
2018 45
2019 51
2020 49
2021 61
2022 40
2023 35
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

569 results

Results by year

Filters applied: . Clear all
Page 1
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.
Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, Shoda H, Mamesaya N, Miyata Y, Okamoto T, Okishio K, Oki M, Sakairi Y, Chen-Yoshikawa TF, Aoki T, Ohira T, Matsumoto I, Ueno K, Miyazaki T, Matsuguma H, Yokouchi H, Otani T, Ito A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Okamoto I, Nakagawa K, Takeda M. Kanemura H, et al. Among authors: nakagawa k. JTO Clin Res Rep. 2024 Mar 8;5(4):100658. doi: 10.1016/j.jtocrr.2024.100658. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38651033 Free PMC article.
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Hayashi H, et al. Among authors: nakagawa k. J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318. J Clin Invest. 2024. PMID: 38557498 Free PMC article.
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA. Smit EF, et al. Among authors: nakagawa k. Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. Lancet Oncol. 2024. PMID: 38547891 Clinical Trial.
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, Tanizaki J, Tamura Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T, Nakamura Y, Sakai K, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: nakagawa k. Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02662-2. Online ahead of print. Br J Cancer. 2024. PMID: 38519705
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Mok T, et al. Among authors: nakagawa k. J Clin Oncol. 2024 Apr 10;42(11):1252-1264. doi: 10.1200/JCO.23.01017. Epub 2024 Jan 22. J Clin Oncol. 2024. PMID: 38252907 Clinical Trial.
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T, Chamoto K, Suzuki S, Kanemura H, Mitani S, Tanaka K, Kawakami H, Kishimoto Y, Haku Y, Ito K, Sato T, Suminaka C, Yamaki M, Chiba Y, Yaguchi T, Omori K, Kobayashi T, Nakagawa K, Honjo T, Hayashi H. Kurosaki T, et al. Among authors: nakagawa k. Front Immunol. 2023 Dec 11;14:1325462. doi: 10.3389/fimmu.2023.1325462. eCollection 2023. Front Immunol. 2023. PMID: 38149256 Free PMC article.
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Shiraishi Y, et al. Among authors: nakagawa k. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi: 10.1001/jamaoncol.2023.5258. JAMA Oncol. 2024. PMID: 38127362 Clinical Trial.
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Sakamoto T, et al. Among authors: nakagawa k. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. JAMA Netw Open. 2023. PMID: 38100106 Free PMC article.
569 results